Monopar Therapeutics (MNPR)
Score window: Apr. 15, 2025 to Apr. 14, 2026
| Date | Form | Sentiment | Urgency | Summary | Open |
|---|---|---|---|---|---|
| Sep. 5, 2025 | CORRESP | Neutral/Informational | Moderate | Monopar Therapeutics Inc. has submitted a request to the U.S. Securities and Exchange Commission to accelerate the effective date of their registration statement on Form S-3 to Se… | Read Filing EDGAR |
| Sep. 4, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has communicated to Monopar Therapeutics that it will not review their registration statement filed on August 29, 2025. This indicates that the company is responsible for … | Read Filing EDGAR |
| Jul. 25, 2025 | UPLOAD | Neutral/Informational | Low | The SEC has completed its review of Monopar Therapeutics' Form 10-K for the fiscal year ended December 31, 2024. They remind the company and its management of their responsibility… | Read Filing EDGAR |
| Jul. 22, 2025 | CORRESP | Concern from SEC | Moderate | Monopar Therapeutics has responded to comments from the SEC regarding its Form 10-K for the fiscal year ended December 31, 2024. The SEC raised concerns about the inclusion of two… | Read Filing EDGAR |
| Jul. 16, 2025 | UPLOAD | Concern from SEC | High | The SEC has reviewed Monopar Therapeutics' Form 10-K for the fiscal year ended December 31, 2024, and has issued several comments requiring clarification and additional disclosure… | Read Filing EDGAR |